7-5/2013/EU/WC-0142 Government of India Directorate General of Health Services Central Drugs Standard Control Organisation (International Cell)

FDA Bhawan, Kotla Road, New Delhi-110002 Dated:

1 1 MAR 2022

To.

M/s. Cipla Limited, Plot No. A-33, A-37/2/2 & A-2, MIDC, Patalganga, Dist. Raigad-410 220 Maharashtra, India

SUB:- Written Confirmation of M/s. Cipla Limited, Plot No. A-33, A-37/2/2 & A-2, MIDC, Patalganga, Dist. Raigad-410 220 Maharashtra, India as per requirement of EU for import of active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India-Reg.

Sir,

Please refer to your online application no. WC/ED/2021/707 submitted to CDSCO, West Zone office and the recommendation received from DDC(I), West Zone office on the above noted subject.

Written Confirmation as required for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC from India is herewith granted subject to the following conditions:-

- The Active Pharmaceutical Ingredients shall confirm to Good Manufacturing Practices mentioned in the EU directives or other equivalent (GMP of WHO/ICH Q7).
- The manufacturer is subject to regular, strict and transparent controls and to the
 effective enforcement of Good Manufacturing Practice, including repeated and
 unannounced inspections, so as to ensure a protection of public health equivalent to
 that in the EU.
- 3. The manufacturer is required to follow the Guidance document for Issue of Written Confirmation as issued by CDSCO.
- 4. Written Confirmation shall be produced by the Authorized Exporter as and when required by the Drug Regulatory Authority.
- 5. The Written Confirmation will be withdrawn in the events of non compliance of Standards.

- This Written Confirmation, unless it is sooner suspended or cancelled, shall be valid for a period of three years.
- 7. In the event of any Non Compliance observed during inspections conducted by Local or International Drug Authorities, the same shall be forwarded to this office within 7 days of receipt of report.
- 8. In the event of any drug found not of standard quality, the same shall be reported to this office within 7 days of receipt of report.

Please note that Written Confirmation issued is liable to be suspended / cancelled, if any of the conditions stipulated above are not complied with or in case of violation of the provisions of the Drugs & Cosmetics Act, 1940 and the Rules thereunder as the case may be.

Please acknowledge the receipt.

Annexure No.	No. of Products	Date of Issue	Valid Upto
1	31	05.08.2019	04.08.2022
2	01	05.08.2019	04.08.2022
3	03	25.02.2022	04.08.2022
4	07	1 1 MAR 2022	04.08.2022
5	. 01	M. 4 MAD 2022	04.08.2022

Yours faithfully,

(Dr. V. G. Somani) Drugs Controller General (India)



CERTIFICATE NO.:

Annexure-4 WC-0142

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

Name and address of site: M/s. Cipla Limited,

Plot No. A-33, A-37/2/2 & A-2, MIDC, Patalganga, Dist. Raigad-410 220

Maharashtra, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
T of NOW	Albuterol Sulfate USP	Manufacturing & Packing
2.	Dutasteride IH	Manufacturing & Packing
3.	Eliglustat Hemitartrate IH	Manufacturing & Packing
4.	Solifenacin Succinate BP/Ph. Eur.	Manufacturing & Packing
5.	Telmisartan BP/Ph. Eur/USP	Manufacturing & Packing
6.DRU	Ticagrelor IH	Manufacturing & Packing
7.	Vortioxetine Hydrobromide IH	Manufacturing & Packing

ITEM(S) SEVEN (07) ONLY

The Written Confirmation remains valid until: 04.08.2022

Signature Vi

Stamp of

he authority and date

1 1 MAR 2022



CERTIFICATE NO.:

WC-0142

Written confirmation for active substances imported into the European Union (EU) for medicinal products for human use, in accordance with Article 46b(2)(b) of Directive 2001/83/EC

1. Name and address of site:

M/s. Cipla Limited,

Plot No. A-33, A-37/2/2 & A-2, MIDC, Patalganga, Dist. Raigad-410 220

Maharashtra, India

List of APIs:

S. No.	Active substance(s)	Activity(ies)
OF ITOM	Efinaconazole IH	Manufacturing & Packing

ITEM(S) ONE (01) ONLY

This certificate is being issued subject to condition that the firm shall obtained NOC from the Competent Authority, on case to case basis, to manufacture the above mentioned active substance for the purpose of export only, as the above mentioned active substance is not approved for manufacture for sale in India

The Written Confirmation remains valid until: 04.08.2022

9 1 MAN 2022

Signature

Stamp

the authority and date